{"id":"inf2-0-ibu","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms (from interferon)"},{"rate":null,"effect":"Gastrointestinal upset (from ibuprofen)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL508802","moleculeType":"Small molecule","molecularWeight":"985.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alpha-2b is a cytokine that enhances immune responses and has antiviral activity, while ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis. The combination aims to leverage both immunomodulation and symptomatic relief, though the clinical rationale for this specific pairing is not well-established in standard literature.","oneSentence":"INF2.0 + IBU is a combination of interferon alpha-2b (INF2.0) and ibuprofen (IBU) that combines antiviral/immunomodulatory effects with anti-inflammatory and analgesic properties.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:33:16.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown — marketed status at St. Justine's Hospital (pediatric center) suggests possible viral infection or immunological indication, but specific approved indication is not documented in standard references"}]},"trialDetails":[{"nctId":"NCT02985177","phase":"PHASE4","title":"A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture","status":"WITHDRAWN","sponsor":"St. Justine's Hospital","startDate":"2020-01","conditions":"Emergency Service, Hospital, Child/Adolescent Problem, Acute Pain","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1517,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"INF2.0 + IBU","genericName":"INF2.0 + IBU","companyName":"St. Justine's Hospital","companyId":"st-justine-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"INF2.0 + IBU is a combination of interferon alpha-2b (INF2.0) and ibuprofen (IBU) that combines antiviral/immunomodulatory effects with anti-inflammatory and analgesic properties. Used for Unknown — marketed status at St. Justine's Hospital (pediatric center) suggests possible viral infection or immunological indication, but specific approved indication is not documented in standard references.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}